US-based biologics discovery contract research organization (CRO) Mosaic Biosciences has entered into a strategic collaboration with clinical-stage drug development company Uniquity Bio to accelerate the discovery and development of novel biologic therapies for immunology and inflammation.
By combining Mosaic’s technology-agnostic discovery platform with Uniquity Bio’s scientific and clinical development capabilities, the companies aim to advance high-quality biologic candidates with the speed and precision that clinical-stage programmes demand.
“We built Mosaic around the belief that the best discovery strategy is one tailored to the biology, not the platform. Uniquity Bio shares that science-first philosophy, and we’re proud to support their mission to bring meaningful new medicines to patients,” said Jean-Pierre Wery, CEO of Mosaic Biosciences.
Kiyomi Komori, Vice President, Translational Medicine of Uniquity, said the partnership extends beyond a traditional CRO relationship.
“Mosaic brings a level of scientific depth and strategic partnership in support of clinical stage and discovery programmes that goes beyond traditional CRO relationships. Their integrated approach and broad discovery capabilities align well with how we think about advancing our pipeline,” Komori said.
Headquartered in Boulder, Colorado, Mosaic Biosciences is a full-service biologics discovery CRO that employs platform-agnostic approaches to drug development. Its capabilities include in vitro display, single B-cell methods, transgenic animal platforms and AI-enabled screening approaches.
Uniquity Bio, based in Malvern, Pennsylvania, is a clinical-stage biotechnology company focused on developing therapies for immunology and inflammatory diseases. Backed by Blackstone Life Sciences, the company is advancing a pipeline of innovative treatments, led by solrikitug, a potent monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) for multiple respiratory and gastrointestinal disorders with high unmet medical need.
